Wedbush Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $12

Benzinga Newsdesk www.benzinga.com Negative 94.3%

Neg 94.3% Neu 0% Pos 0%

Wedbush analyst Yun Zhong maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $15 to $12.